Navigation Links
MED-EL's new MAESTRO
Date:7/9/2008

Durham, NC (July 9, 2008) MED-EL Corporation announced today new data regarding FineHearingTM technology, available only with the MAESTRO Cochlear Implant System. In addition to hearing in "high definition" with FineHearing, MED-EL's MAESTRO system offers the smallest internal implant and the thinnest, lightest externally-worn speech processor available. The MAESTRO CI system presents surgeons with an option of two internal cochlear implants (SONATATI100 or PULSARCI100) and patients with an option of two speech processors (OPUS 1 or OPUS 2), providing the best possible solution for each individual case. The OPUS Speech Processors offer two new sound coding strategies that make hearing the fine details of sound a reality for people who are profoundly deaf.

"The MAESTRO has created a tremendous capacity for patients to hear, they can filter out certain noises, and they can exist in environments that used to be not really well tolerated by people with cochlear implants. The new system has enabled recipients to hear much better than in the past," said Harold C. Pillsbury, MD, Professor and Chairman of the Department of Otolaryngology, Head and Neck Surgery, University of North Carolina at Chapel Hill.

A clinical investigation which evaluated MED-EL's FineHearing technology demonstrated remarkable improvements in music enjoyment and statistically significant improvements in hearing in noisy environments - two areas of hearing that have been challenging for cochlear implant users.1 A questionnaire of patients who participated in the clinical trial showed that 65% reported improved enjoyment of familiar music, while 59% reported improved enjoyment of music that is unfamiliar. Remarkably, 91% of the subjects reported that, in general, music sounds pleasant with their cochlear implant and 82% reported listening to music every week, if not every day. Also, compared to their current processor, more than half reported improvement in sp
'/>"/>

Contact: Rebecca Novak Tibbitt
rebecca@rntcommunications.com
704-341-1544
MED-EL Corporation
Source:Eurekalert  

Page: 1 2 3

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MED-EL's new MAESTRO
MED-EL's new MAESTRO
(Date:12/3/2009)... Now in its 32nd year, the CTRC-AACR San ... in breast cancer science and world leaders from industry ... , This year, more than 8,500 scientists and ... Convention Center in San Antonio from Dec. 9-13, 2009. ...
(Date:12/3/2009)... the design of the upcoming forest deal at Copenhagen in ... at the University of Leeds. , Writing today in ... 50% of the carbon credit payments to be agreed at ... should be made to forest dwellers directly, and their property ...
(Date:12/2/2009)... an increased risk of developing lung cancer in adulthood, even ... are published in Cancer Epidemiology, Biomarkers & Prevention , ... part of a special tobacco focus in the December issue. ... be diagnosed with lung cancer; more than 159,000 will die ...
Breaking Biology News(10 mins):CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 1Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 2Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 3Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 4Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 5Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 6Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 7Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 1Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 2Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 3Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 1Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 2
... (IL-2), an immune-boosting drug used experimentally in HIV therapy, ... system T cells in some HIV-positive people who respond ... of Health (NIH) Clinical Center and the National Institute ... NIH. A report describing the study, led by the ...
... heart attack and unstable angina patients placed on beta-blocker ... to a study by researchers at Washington University School ... Heart Institute in Kansas City. The study appears in ... the American Medical Association. , "In our investigation of ...
... of 72 cases of monkeypox in the United States ... fatality, even though the disease usually kills 10 percent ... patients die? New research from Saint Louis University Health ... answer. , In this month's issue of Virology, researcher ...
Other Biology News:HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 2HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 3Survival of heart patients on beta-blockers varies greatly with genetic variation 2Survival of heart patients on beta-blockers varies greatly with genetic variation 3Survival of heart patients on beta-blockers varies greatly with genetic variation 4Monkeypox mystery: New research may explain why 2003 outbreak in the US wasn't deadly 2
(Date:12/4/2009)... Inc. (OTC Bulletin Board: VIVK) today confirmed that its ... the dividend of shares of common stock of HealthAmerica, ... Directors. HealthAmerica is a private Nevada corporation of ... shares on the record date. The distribution date is ...
(Date:12/4/2009)... Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: ... paradigm through the production of ethanol from non-food cellulosic wastes, ... list of the "50 Hottest Companies in Bioenergy;" the ... "Having voters rank BlueFire Ethanol among the top 20 bioenergy ...
(Date:12/3/2009)... ACCESS PHARMACEUTICALS, INC. (OTC ... European commercial launch of MuGard, an FDA approved treatment ... treatment and chemotherapy. MuGard is commercially launched by Access, ... Germany, Italy, Norway, Greece and Sweden. Access is conducting ...
(Date:12/3/2009)... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that ... of fiscal year 2010 on December 10, 2009 at 7:00 ... to discuss the results at 11:30 a.m. EST on the ... for the second quarter ended October 31, 2009 and will ...
Breaking Biology Technology:Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2
... Although Madison has made a deal with Georgia-based Cellnet ... not be an overnight event. Certain areas will be initially ... Square expected to be approved by the City Council in ... of Madison has taken an active role in brokering Cellnets ...
... At Third Wave Technologies, former vice president Kevin Conroy ... Puisis, who was CEO since mid-2004 and previously held other ... to Third Wave and stayed for a specific purpose," Puisis ... an upgraded, highly-skilled management team in place, that purpose has ...
... Third Wave Technologies ' compensation in a patent lawsuit ... legal fees. Stratagene is proceeding with its appeal. , ... found that Stratagene willfully infringed on two patents covering ... million. , ,Third Wave uses the technology in its ...
Other Biology Technology:Madison wireless deal goes forward with Cellnet 2
... sizes available for use with 96- or 384-well PCR ... for ease of location on 96-tube plates End ... skirt of the plate* Efficient sealing is achieved ... conjunction with screw or clip-down hot lid thermal cyclers ...
... as a wash buffer for Michels Transport Fluid ... for transportation of specimens (such as renal biopsies ... may remain in Transport Fluid for up to ... Fluid is not a fixative and is not ...
... Biotin Streptavidin-HRP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
... can be used with all ... for stacking of covered plates ... use with automated systems ... non-ridged, are available for use ...
Biology Products: